Breaking News

Tweet TWEET

biOasis Announces Positive Anti-Tumour Efficacy Data

biOasis Announces Positive Anti-Tumour Efficacy Data 
biOasis Transcend-Herceptin(R) Conjugate (BT2111) Significantly
Reduces the Number and Size of Metastatic HER2+ Breast Cancer Tumors
in the Brain 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/07/13 -- biOasis
Technologies Inc. (TSX VENTURE:BTI) announced today that its
Transcend-Herceptin(R) Conjugate (BT2111) product candidate (a
proprietary conjugate of Roche's anti-cancer antibody trastuzumab
(Herceptin(R)) and Transcend, biOasis brain delivery vector) reduced
the number of metastatic human HER2+ breast cancer tumors in the
brains of test animals by 68% when compared to untreated control
animals. The tumors that remained after treatment were 57% smaller
than those in the untreated control animals. In contrast, Herceptin
alone had no effect on reducing the number of tumors and was
associated with only a slight (15%) reduction in tumor size when
compared to untreated control animals. These results provide clear
evidence of the potential of the biOasis Transcend-Herceptin(R)
Conjugate (BT2111) for treating brain metastasis. 
The results reported here are from studies performed at Texas Tech
University Health Sciences Center School of Pharmacy under the
direction of Dr. Paul Lockman - a recognized expert on drug transport
across the blood-brain barrier and on metastatic brain tumors. The
study was intended to assess the effect of BT2111 and Herceptin(R)
alone in animals that were inoculated with a human "brain-seeking"
breast cancer cell line that overexpresses HER2. Within 21 days the
cells migrate to the brain and establish clinically relevant tumors.
Animals were then treated twice per week with Herceptin(R) alone, or
the BT2111 conjugate or saline (untreated control) to day 35.
Following treatment the number and size of the metastatic tumors were
then determined. At day 35, the average number of tumors in the
brains of untreated control animals was 85. Herceptin(R) treatment
showed no statistically significant reduction in this number. In
contrast, the animals treated with BT2111 had on average 28 tumors, a
highly statistically significant reduction over both
Herceptin(R)-treated and untreated controls. Furthermore, BT2111
resulted in a 57% reduction in the size of the tumors that remained
after treatment when compared to both Herceptin(R)-treated and
untreated controls. This improvement observed in the BT2111 treatment
group was also highly statistically significant compared to
Herceptin(R) treatment where the average tumor size was slightly
reduced (15%) when compared to untreated controls. 
"The treatment model that Dr. Lockman and his team have developed at
Texas Tech is at the leading edge of research for assessing drug
therapies for metastatic brain cancer. The highly statistically
significant reductions in the number and size of HER2+ metastatic
breast cancer tumors due to BT2111 treatment that biOasis is
reporting today forms part of a massive and rigorous effort to assess
the potential of Transcend Conjugates to traverse the blood-brain
barrier and treat diseases of the brain," said Dr. Wilf Jefferies,
inventor of the Transend technology and Founding Scientist of
biOasis. 
"These studies build on the positive results that we have reported
previously," added Rob Hutchison, biOasis CEO. "In September 2012 we
announced that BT2111 and Herceptin(R) were equally effective in
arresting the growth of breast cancer tumors that were implanted
subcutaneously in test animals. Today we announce the exciting
benefit of BT2111 over Herceptin(R) - that is, the ability to
transport this important anticancer agent into the brain at levels
which are efficacous against metastatic breast carcinomas. Our
mission as a company is to advance the development of BT2111 with the
goal of potentially one day treating this devastating disease that
affects so many women." 
About Brain Metastases of HER2+ Breast Cancer - 20% of human breast
cancers over- express a protein called human epidermal growth factor
receptor 2 (HER2), which promotes the growth of cancer cells. The
standard of care for treatment of these HER2+ cancers is the
monoclonal antibody trastuzumab (Herceptin(R)), which specifically
targets HER2, kills the cancer cells and decreases the risk of
recurrence. Unfortunately, brain metastases of breast cancer occurs
in approximately 35% of women treated with Herceptin(R) for advanced
HER2+ breast cancer. The high incidence of HER2+ metastatic brain
disease results from the combination of the inability of Herceptin(R)
to cross the blood-brain barrier and a predilection of breast cancers
that overexpress HER2 to metastasize to the brain. The prevention and
treatment of brain metastasis from HER2-overexpressing breast tumors
represents a major challenge and there is an urgent medical need for
the development of new treatment strategies. 
About Transcend-Herceptin(R) Conjugate (BT2111) - BT2111 is a
conjugate between biOasis' Transcend brain delivery vector and
trastuzumab (Herceptin(R)), a humanized monoclonal antibody used
clinically in the treatment of HER2+ breast cancer. It is reported
that up to 35% of HER2+ breast cancer patients develop brain
metastasis for which therapeutic options are limited. Because of its
ability to deliver Herceptin(R), across the blood-brain barrier,
biOasis is researching the potential of BT2111 for treatment of HER2+
metastatic breast cancer in the brain. 
Herceptin(R) is a registered trademark of Roche/Genentech. 
ABOUT BIOASIS 
biOasis Technologies Inc. is a biopharmaceutical company
headquartered in Vancouver, Canada. Based on Transcend, biOasis
proprietary brain delivery platform, the Company is focused on
creating new drugs that can cross the blood-brain barrier to address
unmet medical needs in the treatment of brain diseases such as
neurodegeneration, metastatic cancer and metabolic diseases. biOasis
trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca. 
Forward-Looking Statements 
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or developments
express or implied by such forward-looking statements or information.
Such factors include, among others, our stage of development, lack of
any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining
regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and
the prospects for negotiating additional corporate collaborations or
licensing arrangements and their timing. Specifically, certain risks
and uncertainties that could cause such actual events or results
expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include, but
are not limited to, the risks and uncertainties that: we may not be
able to successfully develop and obtain regulatory approval for p97
as a Physician's Aid to Diagnose Alzheimer's, or future products in
our targeted corporate objectives ; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we may
not be able to establish marketing and the costs of launching our
products may be greater than anticipated; we have no experience in
commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in
their entirety by this cautionary statement. All forward-looking
statements and information made herein are based on our current
expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent
events or circumstances, except as required by law. 
On Behalf of the Board of Directors 
Rob Hutchison, Chairman & CEO 
"Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release." 
Contacts:
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778) 383.3280
rob@bioasis.ca
www.bioasis.ca
 
 
Press spacebar to pause and continue. Press esc to stop.